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Abstract: 
Background 
Acute Kidney Injury (AKI) is associated with adverse outcomes; identifying patients 
who are at risk of developing AKI in hospital may lead to targeted prevention. This 
approach is advocated in national guidelines but is not well studied in acutely unwell 
medical patients. We therefore aimed to undertake a UK-wide study in acute medical 
units (AMUs) with the following aims: to define the proportion of acutely unwell medical 
patients who develop hospital-acquired AKI (hAKI); to determine risk factors 
associated with the development of hAKI; and to assess the feasibility of using these 
risk factors to develop an AKI risk prediction score.  
Methods  
In September 2016, a prospective multicentre cohort study across 72 UK AMUs was 
undertaken. Data were collected from all patients who presented over a 24-hour 
period. Chronic dialysis, community-acquired AKI (cAKI) and those with fewer than two 
creatinine measurements were subsequently excluded. The primary outcome was the 
development of h-AKI.   
Results  
2,446 individuals were admitted to the AMUs of the 72 participating centres. 384 
patients (16%) sustained AKI of whom 287 (75%) were cAKI and 97 (25%) were hAKI. 
After exclusions, 1,235 participants remained in whom chronic kidney disease (OR 
3.08, 95% CI 1.96-4.83), diuretic prescription (OR 2.33, 95% CI 1.5-3.65), a lower 
haemoglobin concentration and an elevated serum bilirubin were independently 
associated with development of hAKI. Multivariable model discrimination was 
moderate (c-statistic 0.75), and this did not support the development of a robust clinical 
risk prediction score. Mortality was higher in those with hAKI (adjusted OR 5.22; 95% 
CI 2.23-12.20). 
Conclusion 
AKI in AMUs is common and associated with worse outcomes, with the majority of 
cases community acquired. The smaller proportion of hAKI cases, only moderate 
discrimination of prognostic risk factor modelling and the resource implications of 
widespread application of an AKI clinical risk score across all AMU admissions 
suggests that this approach is not currently justified. More targeted risk assessment or 
automated methods of calculating individual risk may be more appropriate alternatives.  
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Introduction 
The importance of acute kidney injury (AKI) in hospitalised patients is demonstrated 
by its high incidence, strong associations with both short and long-term morbidity and 
mortality, and accompanying health economic burden (1-4)(5). It follows that 
identification of those at risk, if combined with effective strategies for prevention, could 
be highly beneficial. Acutely unwell medical patients represent a particularly important 
population, accounting for the largest percentage of the AKI caseload (6). AKI in this 
group can be divided into those who have already sustained AKI at hospital admission 
(community-acquired AKI, cAKI) and those who sustain AKI during their hospital stay 
(hospital-acquired AKI, hAKI); efforts to reduce AKI risk at time of hospital admission 
will have direct relevance only to hAKI (6). There are many well-described factors that 
increase the risk of AKI including age, presence of co-morbidities, sepsis, previous AKI 
and certain prescribing patterns, but these have not been extensively studied in the 
specific setting of acutely unwell medical patients (7, 8). Moreover, international AKI 
guidelines, including those from the National Institute for Health and Care Excellence 
(NICE, CG169), state that patients with acute illness and who have one or more of 
these factors should be regarded as being at higher risk (9). Practically, however, this 
does not translate into effective risk assessment on an individual patient basis. The 
large number of risk factors, many of which are very common, means that a very high 
percentage of medical patients admitted to hospital have at least one of these. 80% of 
general medical patients over the age of 60 have been reported to have at least one 
AKI risk factor in addition to age alone, consequently this approach does not allow 
reliable discrimination between those at low and higher risk (10).  
A more evolved strategy may be the development of clinical prediction models for AKI 
(11, 12). To date, this has predominantly been described in relatively homogenous 
surgical populations or those scheduled to receive iodinated contrast, where timing of 
potential renal injury is relatively clear  (13-16). Crucially, at least in the setting of 
percutaneous coronary intervention, interventions in response to AKI risk have been 
shown to reduce the incidence of contrast-induced AKI (17). Conversely, there have 
been fewer attempts to apply this “prophylactic” approach to general medical cohorts, 
and where this has been attempted results have been conflicting (9, 18). Furthermore, 
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risk scores have not generally been validated outside of the centres in which they were 
developed, raising concerns about their applicability for widespread adoption.  
We therefore aimed to undertake a UK-wide prospective multicentre observational 
study in acute medical units (AMUs) with the following aims: to define the proportion 
of acutely unwell medical patients who develop hAKI; to determine risk factors 
associated with the development of hAKI; and to assess the feasibility of using these 
risk factors to develop an AKI risk prediction model for medical patients admitted 
acutely.  
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Methods 
Study design, participants and setting 
A prospective multi-centre cohort study was conducted in 72 UK acute medical units 
(AMUs) across England, Wales, Scotland and Northern Ireland in September 2016. A 
full list of centres is included in supplementary material and is available via the study 
website (https://www.kidneyresearchuk.org/research/the-risk-study). The study was 
set up and co-ordinated by members of the national AKI-CSG (Clinical Study Group, 
www.kidneyresearchuk.org/research/acute-kidney-injury-clinical-study-group), who 
also acted as a steering committee for the study. Each centre collected data from all 
patients aged 18 years or older admitted to their AMU over a single 24-hour period. 
Subsequently, patients with cAKI (defined as AKI within the first 24 hours of admission) 
and patients receiving dialysis for end-stage kidney disease were excluded. Patients 
were also excluded if they had fewer than two serum creatinine measurements during 
the hospital admission. Patients were followed up until hospital discharge or day seven 
of admission, whichever was sooner. The study was approved by the Yorkshire and 
Humber NHS Research Ethics committee who waived the requirement for individual 
patient consent. The study did not receive any funding and all investigators voluntarily 
gave their time to complete data collection.  
 
Outcomes and data collection 
Data were collected at the time of admission for a range of parameters that were 
generated from routine clinical care including: demographics; primary reason for 
admission; co-morbidities; medications; physiological observations; urinalysis results; 
laboratory results; and blood gas analysis. The full list of data points collected is 
included in the supplementary material (See Supplementary File 1). All serum 
creatinine results between admission and up to seven days post admission were 
recorded. Where results were not available they were recorded as ‘unknown’. The 
primary outcome was the development of hAKI, defined as a change in serum 
creatinine meeting the KDIGO criteria and occurring >24 hours after hospital admission 
(19). Urine output data were not used to define AKI because hourly urine output 
measurement was frequently unavailable or unlikely to be reliable in the MAU setting. 
Baseline creatinine was defined as the serum creatinine concentration on admission, 
after exclusion of cAKI. Secondary outcomes in patients who sustained hAKI included 
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mortality, need for renal replacement therapy, and requirement for escalation to higher 
level of care. Data were entered into a standardised paper case report form (CRF) and 
subsequently entered into a secure on-line CRF. 
 
Statistical methods 
Data were analysed using the statistical package R (version 3.4.1). A p-value of less 
than 0.05 was regarded as significant. Variables were included for analysis if data were 
available for ≥80% of the study cohort. Continuous predictors were analysed as 
quartiles to adjust for non-linear associations and allow for missing data, with the latter 
included as ‘unknown’.  Univariable analysis was conducted using the Chi-squared test 
to identify differences between the cohort that developed hAKI and those individuals 
that did not. Variables with a p-value of <0.2 were included in the multivariable analysis. 
The multivariable analysis was conducted using binary logistic regression and a 
backwards stepwise procedure to select variables for the final model. The calibration 
of the model was assessed by the Hosmer-Lemeshow goodness-of-fit test. 
Discrimination was assessed using the area under the receiver operating characteristic 
curve (AUROC). 
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Results 
Cohort selection and baseline characteristics 
2,446 individuals were admitted to the AMUs of the 72 participating centres. 1,843 
(75.3%) were admitted via the Emergency Department and the most common reasons 
for admission were chest pain (10.7%); respiratory infection (9.0%); and mobility-
related problems (8.7%). A participant flow diagram is shown in Figure 1. 287 (12%) 
patients had cAKI, 41 (2%) were receiving dialysis for end-stage kidney disease, 865 
(35%) were discharged without a repeat serum creatinine and 18 (1%) did not have 
serum creatinine measured at all. This left 1,235 participants who were included in the 
final analysis. A full description of baseline characteristics of this group is shown (Table 
1). 
 
Development of hAKI 
97 of the 1,235 (7.9%) individuals in the study cohort developed hAKI. If the 
denominator of patients at risk is changed to include the 865 patients with a single 
creatinine measure (to indicate workload from the total population who may potentially 
undergo risk assessment at time of AMU admission), then the proportion of patients 
with hAKI fell to 4.6%. The majority of patients with hAKI were classified as AKI stage 
1 (85 cases, 87% of those with hAKI, 7% of study population), with only 12 cases 
classified as stage 2 or 3 (13% of those with hAKI, 0.9% of study population). 
 
On univariable analysis, the development of any stage of hAKI was associated with a 
number of variables, as shown in Table 2. These included: increased age; a diagnosis 
of hypertension, cardiovascular disease, CKD, atrial fibrillation or heart failure; the 
prescription of diuretics or beta-blockers; a lower body temperature; a low haemoglobin 
concentration; and a high bilirubin level. Notably, individuals with CKD were almost 
four times as likely to develop hAKI (OR 3.94, 95% CI 2.58-6.03) and those prescribed 
diuretics were three times as likely (OR 3.07, 95% CI 2.01-4.67). Variables that were 
not associated with hAKI included admission blood pressure, renin-angiotensin system 
(RAS) inhibitor prescription, non-steroidal anti-inflammatory drug (NSAID) prescription, 
diabetes mellitus and serum markers of inflammation. 
 
The results of the multivariable analysis are shown in Table 3, with factors that 
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remained independently associated with the development of hAKI being CKD stages 
3-5, the prescription of diuretics, a lower haemoglobin concentration and an elevated 
serum bilirubin. We also show two other models for comparison: one that included 
‘conventional’ risk factors for AKI based on NICE guidelines (including CKD and 
diuretic prescription) and the other being a previously published and validated Acute 
Kidney Injury Prediction Score (20, 21). The c-statistic was calculated to examine the 
discrimination of each of the models and was 0.75 (95% CI 0.70-0.80) for the RISK 
model, which although discriminatory was not high enough to proceed to the 
development of a robust clinical risk prediction score. The c-statistic for the other 
models was 0.73 (95% CI 0.67-0.78) for established risk factors and 0.72 (95% CI 
0.67-0.78) for the APS. The ROC curve for the RISK model is shown in Figure 2A. 
Validation analysis using the Hosmer-Lemeshow test suggested good calibration of 
the model (χ2 5.48, P=0.14). A summary of the observed and predicted frequency of 
hAKI with each quintile of risk is shown (Figure 2B).  
 
Outcomes associated with hAKI 
Only one of the 97 individuals who developed hAKI required renal replacement 
therapy. However, hAKI was associated with more adverse outcomes compared to 
those that did not develop AKI. 5/97 (5.1%) of patients who developed hAKI were 
transferred to HDU/ITU, compared to 19/1138 (1.7%) of the patients that did not 
develop hAKI (p=0.05). In addition, 9/97 (9.3%) of the hAKI group died during their 
admission to hospital, compared to 23/1138 (2.0%) of those without hAKI (p< 0.001). 
After adjustment for age, sex and co-morbidities, mortality in individuals with hAKI 
remained significantly higher in comparison to those without (OR 5.22; 95% CI 2.23-
12.20). As an additional comparator, in the cAKI group 13/261 (5.0%) of individuals 
died during hospital admission.  
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Discussion 
We report a large, national cohort study of AKI in UK acute medical units, confirming 
that AKI is common in this group and associated with adverse outcomes, but that 
hospital acquired AKI (hAKI) makes up a relatively small proportion of the cases. We 
identify the most important clinical risk factors for hAKI (including pre-existing CKD and 
diuretic prescription) but our results do not allow the development of a robust risk 
prediction score based upon these clinical variables.  
 
AKI is defined through increases in serum creatinine and/or oliguria; it is therefore a 
syndrome with significant heterogeneity and with many potential causes. The 
incidence of AKI is high and is increasing, with reports suggesting that up to one in five 
hospitalised adults worldwide are affected (1, 2). Our results are consistent with 
published rates of AKI, in that 16% of total AMU admissions sustained AKI. That almost 
three quarters of these patients were cAKI (in which AKI was present on or within the 
first 24 hours of admission) highlights that prompt recognition and treatment of cAKI is 
a priority for AMUs, particularly as evidence is emerging to suggest that a systematic 
focus on basic elements of AKI management may improve outcomes (22-24).  
Conceptually, identifying those at risk of AKI and instituting preventative strategies 
should theoretically translate into reductions in AKI-associated harm. This message 
has been reinforced by observational reports such as the National Confidential Enquiry 
into Patient Outcome and Death, which adjudicated 30.8% of post-admission AKI 
cases as being preventable (25, 26). In an AMU setting, risk assessment is relevant 
only to those who sustain AKI later on during their hospital stay but our data suggest 
that hAKI occurs in a relatively small proportion of patients (4.6% of AMU admissions).  
In part, this reflects current AMU practice in which many patients are discharged after 
a brief hospital stay and without a repeat serum creatinine result, which occurred in 
over a third of our cohort. Furthermore, of the 97 patients who did develop hAKI, only 
12 had AKI stage 2 or 3 (0.9% of the study cohort), and only one patient required renal 
replacement therapy. These findings are consistent with previously published studies 
(25). In those individuals with cAKI efforts should be focussed on prevention of 
worsening AKI and promoting renal recovery.   
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Alongside establishing the number of patients who could potentially benefit from risk 
assessment, the performance of methods to assess AKI risk is also critical. Combining 
the risk factors that we identified into a multivariable model provided at best only a 
moderate ability to discriminate between those who did and did not subsequently 
develop hAKI. A model using ‘recognised’ risk factors for AKI generated an AUC value 
that was only slightly lower (providing CKD and diuretic prescription were included 
because of their strong effect on model performance), and results from a previously 
described single centre clinical risk prediction score were similar. Therefore, these 
results do not support the development of a routine clinical prediction score for use in 
general AMU populations, as the blanket application of such a tool with only moderate 
performance in the setting of a low event rate is likely to generate a significant workload 
in return for limited benefit. However, this does not mean that the risk of AKI should be 
ignored. Outcomes are significantly worse when hAKI does occur, and there are 
examples of effective AKI prevention in other settings; these include a quality 
improvement study in six US hospitals that reduced the incidence of contrast induced 
AKI following percutaneous coronary intervention (17) and a pharmacist-led 
intervention in paediatric patients receiving high risk medications  (27). However, 
before a similar approach can be introduced into AMU settings, further work is required 
to determine how best to ‘operationalise’ risk assessment. Potential strategies may 
include more focussed AKI risk assessment in specific groups rather than all-comers. 
Alternatively, if risk assessment was performed at 24 hours rather than admission, it 
may be possible to have more focussed approach by excluding the 35% of low-risk 
patients who had no repeat creatinine and a short length of stay. More sophisticated 
computational methods of real-time rolling risk assessment that do not require manual 
data entry, or the addition of new AKI biomarkers to improve performance of a clinical 
risk score may also be ways of improving risk assessment (28). The latter approach 
has shown to be successful in a paediatric ICU setting (29), and a recent pilot study in 
a UK AMU setting has demonstrated that the addition of a biomarker to the APS clinical 
prediction tool has potential utility to identify low risk groups, with a negative predictor 
value for hAKI that approached 97% (Hodgson et al in press).  
 
Several of the risk factors that we observed to be associated with the development of 
hAKI were expected (such as increasing age, co-morbidities such as CKD and heart 
failure); of these, pre-existing CKD and diuretic prescription at time of admission had 
Commented [NS1]: No longer in press! Can add 
reference 
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the strongest associations and may identify a group of particular interest. Some factors 
that are recognised as potential risk factors for AKI were not strongly associated with 
hAKI in this setting, for example RAS inhibitors, admission blood pressure or diabetes 
mellitus. In addition, laboratory tests that may not traditionally be considered AKI risk 
factors (low haemoglobin, high bilirubin) were independently associated with hAKI in 
our population. These findings emphasise that the development of methods to assess 
risk of AKI should be based on evidence derived from the populations in which they 
are intended to be used. This is particularly true in view of the heterogeneity in 
aetiology of AKI across patient groups. Our national approach incorporating 72 centres 
coupled to data collection encompassing a wide range of patient characteristics, 
physiological data, prescribing information and laboratory results, provides results that 
are likely to be applicable to AMUs in the UK and possibly in other similar healthcare 
settings. Our comprehensive approach to data collection also suggests there is limited 
room from improving risk prediction in this setting using clinical variables alone. In the 
future, application of risk algorithms embedded within electronic patient records may 
facilitate identification of high risk cases.  
 
Our study does have some weaknesses. AKI was defined using only serum creatinine 
and patients who developed AKI solely defined by urine output criteria would have 
been missed. However, our data also show that applying urine output criteria in this 
population where most patients do not have a urethral catheter is not practical (only 
11% of patients had hourly urine output recorded). In addition, using the first creatinine 
of hospital admission as a baseline value may potentially have resulted in under-
recognition of hAKI (for example, if creatinine had already begun to rise but not 
reached KDIGO definition of AKI at time of admission) although the effects of this are 
likely to be small. The data collection period was short, and it is possible that results 
may have been different at a different time of year (e.g. higher incidence of AKI in 
winter). Also patients admitted directly to higher levels of care such as ICU or HDU 
were not captured which may have led to an underestimation of the incidence of AKI.  
Finally, because of logistical considerations we did not collect data on longer term 
outcomes after hospital discharge (e.g. renal recovery, hospital readmission rates) that 
would have been informative.  
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Conclusions 
AKI remains a significant clinical problem in acutely unwell medical patients. The 
majority of cases are community acquired, so the prompt recognition and treatment of 
these patients in AMUs is a clear priority. The smaller proportion of hAKI cases and 
only moderate discrimination of prognostic risk factor modelling suggests that the 
increased workload that would be required to apply a manual AKI clinical risk score 
across all AMU admissions using currently available techniques is not currently 
justified. More targeted risk assessment or automated methods of calculating 
individual risk may be more appropriate alternatives, but would require evaluation in 
future studies. 
 
 
 
 
 
 
 
 
 
 
 
 
  
  13 
 
Table 1. Cohort characteristics 
 All individuals  
(n=1,235) 
Age, years (median, IQR) 73 (56–83) 
Female sex (n, %) 632 (51) 
Length of stay in days (median, IQR) 5 (3-7) 
Admission via ED (n, %) 932 (75) 
Reason for admission (n, %): 
  Respiratory tract infection 
  Fall or mobility problem 
  Chest pain 
  Abdominal pain 
  Asthma or chronic obstructive lung disease 
  Dizzyness and/or collapse 
  Delirium 
  Soft tissue infection and/or ulcer 
  Diarrhoea and/or vomiting 
  Urinary tract infection 
  Gastrointestinal bleeding 
  Deliberate self-harm and drug overdose 
  Heart failure 
  Thromboembolic disease 
  Reduced consciousness and/or seizure 
  Stroke or transient ischaemic attack 
  Other reason 
 
149 (11) 
108 (9) 
99 (8) 
71 (6) 
66 (5) 
65 (5) 
61 (5) 
51 (4) 
49 (4) 
48 (4) 
39 (3) 
39 (3) 
36 (3) 
20 (2) 
19 (2) 
13 (1) 
302 (24) 
  14 
Co-morbidity (n,%): 
  Hypertension 
  Cardiovascular disease 
  Diabetes mellitus (type I or II) 
  Chronic kidney disease 
  Atrial fibrillation 
  Chronic obstructive lung disease 
  Heart failure 
  Active malignancy 
  Dementia 
  Liver disease 
 
436 (35) 
360 (29) 
278 (23) 
266 (22) 
203 (16) 
199 (16) 
156 (13) 
149 (12) 
113 (9) 
85 (7) 
Medication (n, %): 
  Diuretic 
  Beta-blocker 
  Renin angiotensin system inhibitor 
  Other antihypertensive 
  Corticosteroid 
  Oral hypoglycaemic agent 
  Non-steroidal anti-inflammatory 
  Insulin 
  Other chemotherapy/immunosuppression 
 
314 (25) 
298 (24) 
285 (23) 
223 (18) 
196 (16) 
159 (13) 
94 (8) 
76 (6) 
51 (4) 
Observations (median, IQR): 
  Systolic blood pressure, mmHg 
  Diastolic blood pressure, mmHg 
  Pulse rate, per minute 
  Respiratory rate, per minute 
  Temperature, degrees Celsius 
  Supplemental oxygen requirement  (n, %) 
  AVPU score, not ‘Alert’ (n, &) 
 
129 (114-146) 
72 (64-82) 
72 (73-98) 
18 (16-20) 
36.6 (36.3-37.1) 
339 (29) 
59 (5) 
  15 
Blood tests (median, IQR): 
  Haemoglobin, g/L 
  White blood cells, x109/L 
  Platelets, x109/L 
  Sodium, mmol/L 
  Potassium, mmol/L 
  Urea, mmol/L 
  Creatinine, υmol/L 
  Bilirubin, υmol/L 
  Albumin, g/L 
  ALT, U/L 
  CRP, mg/L 
 
126 (113-139) 
9.5 (7.0-12.9) 
245 (188-317) 
137 (134, 140) 
4.2 (3.9, 4.6) 
6.1 (4.4, 8.6) 
79 (63, 102) 
10 (7, 16) 
37 (32, 41) 
19 (13, 31) 
23 (5, 80) 
Abbreviations: n, number of individuals; %, percentage of individuals; IQR, inter-
quartile range; ED, emergency department; AVPU, (scale) Alert Voice Pain 
Unconscious; ALT, alanine aminotransferase; CRP, C-reactive peptide  
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Table 2. Comparison of HAKI cohort with controls 
 No AKI 
(n = 1138) 
 
hAKI 
(n = 97) 
P-value 
Age quartiles, years: 
  ≤ 56 
  57-73 
  74-83 
  ≥ 84 
  Unknown 
 
309 (27) 
278 (24) 
286 (25) 
263 (23) 
2 (0) 
 
12 (12) 
31 (32) 
28 (29) 
26 (27) 
0 (0) 
0.03 
 
 
 
 
Female sex 585 (51) 47 (48) 0.65 
Co-morbidity: 
  Hypertension 
  Cardiovascular disease 
  Diabetes mellitus (type I or II) 
  Chronic kidney disease 
  Atrial fibrillation 
  Chronic obstructive lung disease 
  Heart failure 
  Active malignancy 
  Dementia 
  Liver disease 
 
391 (34) 
322 (28) 
252 (22) 
219 (19) 
176 (15) 
179 (16) 
128 (11) 
136 (12) 
106 (9) 
76 (7) 
 
46 (46) 
38 (39) 
26 (27) 
47 (48) 
27 (28) 
20 (21) 
28 (29) 
13 (13) 
7 (7) 
9 (9) 
 
0.02 
0.03 
0.35 
<0.001 
0.003 
0.27 
<0.001 
0.80 
0.61 
0.45 
Medication: 
  Diuretic 
  Beta-blocker 
  Renin angiotensin system inhibitor 
  Other antihypertensive 
  Corticosteroid 
  Oral hypoglycaemic agent 
 
267 (23) 
262 (23) 
258 (23) 
205 (18) 
179 (16) 
150 (13) 
 
47 (48) 
36 (37) 
27 (28) 
18 (19) 
17 (18) 
9 (9) 
 
<0.001 
<0.01 
0.30 
1.00 
0.75 
0.35 
Commented [JP2]:  
 
  17 
  Non-steroidal anti-inflammatory 
  Insulin 
  Other chemotherapy/immunosuppression 
85 (7) 
67 (6) 
46 (4) 
9 (9) 
9 (9) 
5 (5) 
0.66 
0.27 
0.79 
Observations: 
  Systolic blood pressure quartiles, mmHg  
     ≤ 114 
     115 - 129 
     130 - 146 
      ≥ 147 
    Unknown 
  Diastolic blood pressure quartiles, mmHg 
    ≤ 64 
    65 - 72 
    73 - 82 
    ≥ 83 
    Unknown 
  Pulse rate quartiles, per minute 
    ≤ 73 
    74 - 85 
    86 - 98 
    ≥ 99 
   Unknown 
  Respiratory rate quartiles, per minute 
    ≤ 16 
    17 - 18 
    19 - 20 
     ≥ 21 
 
 
290 (25) 
280 (25) 
284 (25) 
277 (24) 
7 (1) 
 
280 (25) 
285 (25) 
291 (26) 
265 (23) 
8 (1) 
 
300 (26) 
306 (27) 
258 (23) 
268 (24) 
6 (1) 
 
357 (31) 
348 (31) 
214 (19) 
205 (18) 
 
 
28 (29) 
17 (18) 
24 (25) 
28 (29) 
0 (0) 
 
30 (31) 
21 (22) 
18 (19) 
28 (29) 
0 (0) 
 
22 (23) 
21 (22) 
24 (25) 
30 (31) 
0 (0) 
 
24 (25) 
27 (28) 
22 (23) 
23 (24) 
 
0.46 
 
 
 
 
 
0.28 
 
 
 
 
 
0.39 
 
 
 
 
 
0.43 
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    Unknown 
  Body temperature quartiles, degrees celcius 
    ≤ 36.3 
    36.4 - 36.6 
    36.7 - 37.1 
    ≥ 37.2 
   Unknown 
Supplemental oxygen requirement 
AVPU score, not ‘Alert’ 
14 (1) 
 
293 (26) 
266 (23) 
292 (26) 
273 (24) 
14 (1) 
809 (28) 
55 (5) 
1 (1) 
 
39 (40) 
17 (18) 
22 (23) 
19 (20) 
0 (0) 
30 (31) 
4 (4) 
 
0.03 
 
 
 
 
 
0.52 
0.95 
Blood tests 
  Haemoglobin quartiles, g/L 
    ≤ 113 
    114 - 126 
    127 - 139 
    ≥ 140 
    Unknown 
  White blood cell quartiles, x109/L 
    ≤7.0 
    7.1 - 9.5 
    9.6 - 12.9 
    ≥ 13.0 
    Unknown 
  Platelet quartiles, x109/L 
    ≤ 188 
    189 - 245 
    246 - 317 
    ≥ 318 
    Unknown 
  Serum sodium quartiles, mmol/L 
    ≤ 134 
 
 
278 (24) 
273 (24) 
283 (25) 
291 (26) 
14 (1) 
 
289 (25) 
282 (25) 
276 (24) 
274 (24) 
17 (1) 
 
282 (25) 
280 (25) 
286 (25) 
276 (24) 
14 (1) 
 
286 (25) 
 
 
39 (40) 
27 (28) 
15 (15) 
14 (14) 
2 (2) 
 
19 (20) 
28 (29) 
19 (20) 
29 (30) 
2 (2) 
 
22 (23) 
26 (27) 
22 (23) 
24 (25) 
3 (3) 
 
29 (30) 
 
<0.01 
 
 
 
 
 
0.40 
 
 
 
 
 
0.59 
 
 
 
 
 
0.36 
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    135 - 137 
    138 - 140 
    ≥ 141 
    Unknown 
   Potassium quartiles, mmol/L 
    ≤ 3.9 
    4.0 - 4.2 
    4.3 - 4.6 
    ≥ 4.7 
    Unknown 
  Bilirubin quartiles, υmol/L 
    ≤ 7 
    8 - 10 
    11 - 16 
    ≥ 17 
    Unknown 
  Albumin quartiles, g/L 
    ≤ 32 
    33 - 37 
    38 - 41 
    ≥ 42 
    Unknown 
  ALT quartiles, U/L 
    ≤ 13 
    14 - 19 
    20 - 31 
    ≥ 32 
    Unknown 
  CRP quartiles, mg/L 
    ≤ 5 
274 (24) 
329 (29) 
244 (21) 
5 (0) 
 
324 (28) 
258 (23) 
268 (24) 
201 (18) 
87 (8) 
 
285 (25) 
230 (20) 
243 (21) 
229 (20) 
151 (13) 
 
247 (22) 
280 (25) 
231 (20) 
204 (18) 
176 (15) 
 
270 (24) 
217 (19) 
216 (19) 
230 (20) 
205 (18) 
 
257 (23) 
29 (30) 
22 (23) 
17 (18) 
0 (0) 
 
26 (27) 
29 (20) 
17 (18) 
26 (27) 
9 (9) 
 
20 (21) 
14 (14) 
15 (15) 
34 (35) 
14 (14) 
 
23 (24) 
28 (29) 
12 (12) 
15 (15) 
19 (20) 
 
21 (22) 
22 (23) 
11 (11) 
21 (22) 
22 (23) 
 
14 (14) 
 
 
 
 
0.18 
 
 
 
 
 
<0.01 
 
 
 
 
 
0.29 
 
 
 
 
 
0.31 
 
 
 
 
 
0.22 
 
  20 
    6 - 22 
    23 - 80 
    ≥ 81 
   Unknown 
206 (18) 
233 (20) 
241 (21) 
201 (18) 
18 (19) 
28 (29) 
20 (21) 
17 (18) 
 
 
 
 
Abbreviations: AVPU, (scale) Alert Voice Pain Unconscious; ALT, alanine aminotransferase; CRP, C-
reactive peptide 
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Table 3. Comparison of multivariate models 
 Classical risk factors APS RISK Study model 
 Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value 
Age, years 
  < 60 
   60-79 
   ≥ 80 
 
REF 
1.41 (0.74-2.66) 
1.17 (0.60-2.28) 
 
REF 
0.29 
0.65 
 
REF 
1.53 (0.81-2.87) 
1.30 (0.67-2.52) 
 
REF 
0.19 
0.44 
 
- 
- 
- 
 
- 
- 
- 
Co-morbidity 
  Chronic kidney disease 
  Diabetes mellitus (type I or II) 
  Cardiovascular diseasea 
  Heart failure 
  Liver disease 
 
3.44 (2.11-5.60) 
0.80 (0.47-1.35) 
0.97 (0.60-1.55) 
1.50 (0.85-2.65) 
1.36 (0.49-3.81) 
 
<0.001 
0.40 
0.88 
1.16 
0.55 
 
3.42 (2.12-5.51) 
0.82 (0.49-1.37) 
- 
2.15 (1.29-3.58) 
1.82 (0.83-3.96) 
 
<0.001 
0.45 
- 
<0.01 
0.13 
 
3.08 (1.96-4.83) 
- 
- 
- 
- 
 
<0.001 
- 
- 
- 
- 
Medication 
  Diuretic(s) 
  Renin angiotensin system inhibitor 
  Non-steroidal anti-inflammatory 
 
2.14 (1.30-3.50) 
1.02 (0.62-1.69) 
1.66 (0.78-3.55) 
 
<0.01 
0.94 
0.19 
 
- 
- 
- 
 
- 
- 
- 
 
2.33 (1.50-3.64) 
- 
- 
 
<0.001 
- 
- 
Observations 
  Respiratory rate  ≥ 20 per min 
  AVPU score, not ‘Alert’ 
 
- 
- 
 
- 
- 
 
1.55 (1.00-2.40) 
0.76 (0.26-2.23) 
 
0.05 
0.62 
- 
- 
- 
- 
Blood tests 
  Haemoglobin, g/L 
      ≥ 140 
      127 - 139 
      114 - 126 
      ≤ 113 
      Unknown 
  Bilirubin, υmol/L 
      ≤ 7 
 
 
- 
- 
- 
- 
- 
 
- 
 
 
- 
- 
- 
- 
- 
 
- 
 
 
- 
- 
- 
- 
- 
 
- 
 
 
- 
- 
- 
- 
- 
 
- 
 
 
REF 
1.03 (0.48-2.21) 
1.75 (0.87-3.50) 
2.22 (1.14-4.34) 
3.26 (0.64-16.56) 
 
REF 
 
 
REF 
0.95 
0.11 
0.02 
0.15 
 
REF 
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      8 - 10 
      11-16 
      ≥ 17 
      Unknown 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0.93 (0.45-1.92) 
0.96 (0.47-1.97) 
2.33 (1.26-4.28) 
1.50 (0.72-3.14) 
0.84 
0.91 
<0.01 
0.28 
AUROC (95% CI) 0.73 (0.67-0.78) 0.72 (0.67, 0.78) 0.75 (0.70-0.80) 
  23 
2,100 WITHOUT cAKI 
AND AT RISK OF hAKI 
INITIAL COHORT:  
2,446 INDIVIDUALS 
18 individuals with 
ESRD receiving dialysis 
287 individuals with  
cAKI (12.0%) 
865 individuals without a 
repeat creatinine after 
admission  
41 individuals without a 
creatinine on admission  
2,387 INDIVIDUALS 
STUDY COHORT: 
1,235 INDIVIDUALS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow diagram illustrating cohort-selection process. Abbreviations: cAKI, community-acquired 
AKI; hAKI, hospital-acquired AKI; ESRD, end-stage renal disease 
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A. B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A). ROC curve for RISK model; (B). Hosmer-Lemeshow calibration plot demonstrating the 
observed and predicted frequency of hAKI with each quintile of risk. 
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